Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off

References

• Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001;19:1013–38
   Google Scholar
• LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics 1999;16:59–69
   Google Scholar
• Keränen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003;9:163–8
   PubMed Web of Science ®Google Scholar
• Hagell P, Nordling S, Reimer J, et al. Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov Disord 2002;17:1213–20
   PubMed Web of Science ®Google Scholar
• Ruottinen HM, Rinne UK. Effect of one month’s treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222–33
   PubMed Web of Science ®Google Scholar
• Anonymous. Entacapone/Levodopa/Carbidopa Combination Tablet: Stalevo™. Drugs R&D 2003;4:310–1
   PubMedGoogle Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997;42:747–55
   PubMed Web of Science ®Google Scholar
• Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309–14
   PubMed Web of Science ®Google Scholar
• Myllylä VV, Kultalahti ER, Haapaniemi H, et al. Twelve-month safety of entacapone in patients with Parkinson’s disease. Eur J Neurol 2001;8:53–60
   Google Scholar
• Brooks DJ, Sagar H for the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:1071–79
   Google Scholar
• Poewe WH, Deuschi, Grodin A, et al. for the Celomen Study Group. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105: 245–55
   Google Scholar
• Durif F, Devaux I, Pere JJ, et al. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001;45:111–18
   PubMed Web of Science ®Google Scholar
• Gershanik O, Emre M, Bernhard G, et al. Efficacy and safety of levodopa with entacapone in Parkinson’s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:963–71
   PubMed Web of Science ®Google Scholar
• Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm 2004;11:1053–63
   Google Scholar
• Brooks DJ, Agid Y, Eggert K, et al. and the TC-INIT Study Group. Treatment of end-of-dose wearing-off in Parkinson’s disease: Stalevo® (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess®/Comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. European Neurology. (Manuscript accepted March 2005)
   Google Scholar
• Henchcliffe C, Waters C. Entacapone in the management of Parkinson’s disease. Expert Opin Pharmacother 2002;3:957–63
   PubMedGoogle Scholar
• Factor SA, Molho ES, Feustel PJ, et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol 2001;24;295–99
   PubMed Web of Science ®Google Scholar
• Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics 2002;20:617–28
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis. Value Health 2001;4:316–28
   PubMedGoogle Scholar
• Linna M, Taimela E, Apajasalo M, et al. Probabilistic sensitivity analysis for evaluating cost-effectiveness of entacapone for Parkinson’s disease. Expert Rev Pharmacoeconomics Outcomes Res 2002;2:91–7
   PubMedGoogle Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397–409
   PubMed Web of Science ®Google Scholar
• Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157–77
   PubMedGoogle Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;7:479–500
   Google Scholar
• Levy AR, Briggs AH, Demers C, et al. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 2001;142:537–43
   PubMed Web of Science ®Google Scholar
• Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002;20:183–94
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42
   PubMed Web of Science ®Google Scholar
• Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139–45
   PubMed Web of Science ®Google Scholar
• Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone – a review. J Neural Transm 2004;111:1343–63
   Google Scholar
• Chemist and Druggist Price List. Available from http://www.candnet.com/home.asp [Last accessed 21 Feb 2005]
   Google Scholar
• Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112–8
   Google Scholar
• Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord 1995;10:250–6
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293–9
   Google Scholar
• Sendi P, Clemen R. Sensitivity analysis on a chance node with more than two branches. Med Decis Making 2000;20:314–22
   PubMedGoogle Scholar
• Rafferty J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323:1300–3
   PubMed Web of Science ®Google Scholar
• Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat Med 2001;20:1563–74
   PubMed Web of Science ®Google Scholar
• O’Hagan A, Stevens J, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000;17:339–48
   Google Scholar
• National Institute for Clinical Excellence. Parkinson’s disease: diagnosis, management and treatment of adults with Parkinson’s disease in primary and secondary care. Available from http://www.nice.org.uk/page.aspx?o=213723 [Last accessed 14 Feb 2005]
   Google Scholar
• Poewe W. The role of COMT inhibition in the treatment of Parkinson’s disease. Neurology 2004;13;62\(Suppl 1):S31–8
   Google Scholar
• Larsen JP, Worm-Petersen J, Siden A, et al. for the NOMESAFE Study Group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease. Eur J Neurol 2003;10:137–46
   Google Scholar
• Klein R. Britain’s national health service revisited. N Engl J Med 2004;350:937–42
   PubMed Web of Science ®Google Scholar
• National Standards, Local Action: Health and Social Care Standards and Planning Framework 2005/06–2007/08. UK Department of Health. July 2004. Available from http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4086057&chk=ypFWoL [Last accessed 14 Feb 2005]
   Google Scholar
• Nuijten MJ. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations. Pharmacoeconomics 2004;22:759–69
   PubMed Web of Science ®Google Scholar